Dyadic announces publication of c1 monoclonal antibody in nonhuman primate study in nature communications

Jupiter, fla., march 26, 2024 (globe newswire) -- dyadic international, inc. (“dyadic” or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript "filamentous fungus-produced human monoclonal antibody provides protection against sars-cov-2 in hamster and nonhuman primate models" in nature communications (“springer-nature"), an international journal publishing peer-reviewed research in all fields of science and technology.
DYAI Ratings Summary
DYAI Quant Ranking